Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
about
The role of preoperative systemic treatment in patients with breast cancerCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyNeoadjuvant therapy in the treatment of breast cancerExploring circulating micro-RNA in the neoadjuvant treatment of breast cancerNeoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancerTrends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.Local treatment of the axilla in early breast cancer: concepts from the national surgical adjuvant breast and bowel project B-04 to the planned intergroup sentinel mamma trialMonitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypesAccuracy of axillary ultrasound after different neoadjuvant chemotherapy cycles in breast cancer patients.Assessment of early treatment response to neoadjuvant chemotherapy in breast cancer using non-mono-exponential diffusion models: a feasibility study comparing the baseline and mid-treatment MRI examinationsChemotherapy in early breast cancer: when, how and which one?Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy.Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapyTumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyondWomen with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival.Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differentiaPathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator.ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast CancerMeta-analysis of the concordance of histological grade of breast cancer between core needle biopsy and surgical excision specimen.CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patientsPathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.The accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.Assessment of Pathological Response of Breast Carcinoma in Modified Radical Mastectomy Specimens after Neoadjuvant Chemotherapy.Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.The Role of Postmastectomy Radiation Therapy in Patients With Breast Cancer Responding to Neoadjuvant ChemotherapyEstradiol, TGF-β1 and hypoxia promote breast cancer stemness and EMT-mediated breast cancer migrationTen-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy.Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational studyIncreased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancerTargets for Neoadjuvant Therapy - The Preferences of Patients with Early Breast Cancer.The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies.Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapyA Decision Aid for Women Considering Neoadjuvant Systemic Therapy for Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study (ANZ1301 DOMINO).SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer.
P2860
Q26746034-76A4E953-A687-415D-9AE8-E0B603AD6039Q27011658-9D8751D4-B35D-4D54-9D07-BD7B45970DCCQ27694514-8033943C-C8F9-4F9F-AF8C-1E63FC76C4E3Q28066481-4944637B-C0DF-4870-9D1B-1F24E6D68A75Q28706276-FE472891-42A9-42EF-B73C-DB9981A0BDFEQ31132822-8827152D-DFC5-4B59-ADC7-69A59CEE922FQ31150366-BE34D63E-DBB3-4E4B-843E-AA049D9631DEQ33684856-6FD50E29-4207-4EFD-A64A-989EBA2535ACQ33712925-DCCD0076-AFCE-44F7-8454-3F5534C16E8AQ33829617-A9FFB5B3-0EE7-4C34-B3DD-11ED259F169EQ33841446-EDF6AB5D-E0FB-4E22-B58E-B8B8911E680DQ34042640-E5773409-0F07-48E3-8F4F-D06E9CF341CAQ34265841-E12868A3-BD6A-4640-B834-DB325653075EQ34501788-3CDD4843-1EB2-49F8-A5BB-B11BD811C9C0Q35000651-82B96E67-B5CF-4B6C-93CB-B6C55892CB49Q35239617-658DA3D7-2D7D-4EC9-80FB-D856063B3660Q35599471-366E9C5B-4958-48A2-8CE7-EB4CF1E07481Q35743162-95608F77-EB53-4502-A5F0-3B45082560B5Q35803615-92F8A40E-E44E-468B-BB3A-C7242463BF1AQ35823740-EBEBA9D0-E25F-4740-9EB6-D1855E651D32Q35881343-65AC6361-9977-4B34-B597-16269F2462F7Q35920570-41B16943-F72C-46F1-B838-B42869A98559Q35962498-B54A334A-5EAA-4A78-A030-923C18D41F19Q35974459-01F2F9AB-CBAC-4E64-A153-813D601F9C57Q36132952-E5EE2A99-80D4-452E-B464-BCF542330DE0Q36364739-53243143-A8A0-42C3-8494-CF447314DF8CQ36366929-2643B9FF-CFA9-4270-B582-E7A8DC533267Q36419147-C4ED5E8C-CC4E-4383-85F6-8A1FCBF848C6Q36478592-D7E46880-3AEC-4E1D-B360-C8114B7E1DB0Q36640378-A529D59E-08DF-4979-B481-965AD84E6B3EQ36838312-B3093DB5-2A37-4AC6-884F-136A8A82E3C6Q36868191-FFD1A336-3E8B-416F-B32F-DB17110D3B81Q36889647-B8CC67E3-B1C8-4861-8CF9-EC85CA94F0EDQ36917634-93270888-3FFF-4A93-9DF1-3A8BA3B54451Q36922539-7C279C73-E327-4F59-9880-13B09A0D609FQ36952188-EEB383A6-508A-4D0F-81BC-28790AD21398Q36968921-0519D6AF-25B1-47B3-85C2-4E475F9F6F30Q37131869-D1C389B5-BDC8-48EF-B0AA-20FE89158228Q37185832-D786ACF9-1947-4C1A-B61A-E8BDB81A395EQ37288041-1A7902E1-7FE0-4591-9EC3-967EF59FC1A7
P2860
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recommendations from an intern ...... rapy in primary breast cancer.
@en
Recommendations from an intern ...... rapy in primary breast cancer.
@nl
type
label
Recommendations from an intern ...... rapy in primary breast cancer.
@en
Recommendations from an intern ...... rapy in primary breast cancer.
@nl
prefLabel
Recommendations from an intern ...... rapy in primary breast cancer.
@en
Recommendations from an intern ...... rapy in primary breast cancer.
@nl
P2093
P50
P1476
Recommendations from an intern ...... erapy in primary breast cancer
@en
P2093
Andrew Tutt
Cornelia Liedtke
David Cameron
Davide Mauri
Elefhterios P Mamounas
Eugen Ruckhaeberle
Jay R Harris
Lajos Pusztai
Lisa A Carey
Manfred Kaufmann
P2888
P304
P356
10.1245/S10434-011-2108-2
P577
2011-12-23T00:00:00Z
P6179
1011255060